Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

被引：14
|
作者：
Buti, Sebastiano [1 ]
Bersanelli, Melissa [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 16期
关键词：
TRIAL; THERAPY;
D O I：
10.1200/JCO.2016.71.6506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1858 / +
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [22] COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
    Skentzou, E.
    Meng, J.
    Lister, J.
    Gray, L.
    VALUE IN HEALTH, 2018, 21 : S30 - S30
  • [23] Risk of treatment failure after first-line sunitinib therapy in patients with metastatic renal cell carcinoma.
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Hill, Jerrold W.
    Guo, Min Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] COST EFFECTIVENESS OF CABOZANTINIB PLUS NIVOLUMAB AS FIRST-LINE TREATMENT FOR RENAL CELL CARCINOMA
    Marciniak, A.
    Gultyaev, D.
    Orbzut, G.
    Mollon, P.
    Wallace, J. F.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S301
  • [25] Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
    Pill, Roberto
    Pal, Sumanta Kumar
    George, Saby
    Voortman, Jens
    Danchalvijitr, Pongwut
    Adelalye, Remi
    Webb, Nancy
    Poslinski, Diane
    Groman, Adrienne
    Hutson, Alan
    Verheul, Honk M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry
    Boegemann, Martin
    Hubbe, Marcus
    Thomaidou, Despina
    Blackburn, Stuart
    Bent-Ennakhil, Nawal
    Wood, Robert
    Bargo, Danielle
    ANTICANCER RESEARCH, 2018, 38 (11) : 6413 - 6422
  • [27] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2018, 34 (10) : 457 - 465
  • [29] Advanced Renal Cell Carcinoma Cabozantinib is a recommended Treatment Option for First-line Therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 150 - 151
  • [30] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
12345